The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Open accessAbstract
Amphotericin B is the treatment of choice for life-threatening systemic fungal infections such as candidosis and aspergillosis. To improve this drug's efficacy and reduce its acute and chronic toxicities, several lipid formulations of the drug have been developed, including AmBisome, a liposomal formulation of amphotericin B. The liposome is composed of high transition temperature phospholipids and cholesterol, designed to incorporate amphotericin B securely into the liposomal bilayer. AmBisome can bind to fungal cell walls, where the liposome is disrupted. The amphotericin B, after being released from the liposomes, is thought to transfer through the cell wall and bind to ergosterol in the fungal cell membrane. This mechanism of action of AmBisome results in its potent in vitro fungicidal activity while the integrity of the liposome is maintained in the presence of mammalian cells, for which it has minimal toxicity. In animal models, AmBisome is effective in treating both intracellular (leishmaniasis and histoplasmosis) and extracellular (candidosis and aspergillosis) systemic infections. Because of its low toxicity at the organ level, intravenous AmBisome can be safely delivered at markedly high doses of amphotericin B (1–30 mg/kg) for the treatment of systemic fungal infections. AmBisome has a circulating half-life of 5–24 h in animals, and in animal models appears to localize at sites of infection in the brain (cryptococcosis, aspergillosis, coccidioidomycosis), lungs (blastomycosis, paracoccidioidomycosis, aspergillosis) and kidneys (candidosis), delivering amphotericin B that remains bioavailable in tissues for several weeks following treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Papahadjopoulos, D., Jacobson, K., Nir, S., & Isac, I. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90314-3 · Cited by 997
Groll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373
Adler-moore, J. P., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 251
Self-citationPharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
Proffitt, R. T., Satorius, A., Chiang, S.-M., Sullivan, L., & Adler-Moore, J. P. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.49 · Cited by 203
Self-citationFrancis, P., Lee, J. W., Hoffman, A., Peter, J., Francesconi, A., Bacher, J., Shelhamer, J., Pizzo, P. A., & Walsh, T. J. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/169.2.356 · Cited by 185
The Formation of Amphotericin B Ion Channels in Lipid Bilayers
Fujii, G., Chang, J.-E., Coley, T. R., & Steere, B. A. (1997) · Biochemistry · doi:10.1021/bi962894z · Cited by 148
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134
AmBisome targeting to fungal infections.
Adler‐Moore, J. (1994) · PubMed · Cited by 107
Self-citationComparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B
Anaissie, E. J., Paetznick, V. L., Proffitt, R. T., Adler‐Moore, J., & Bodey, G. P. (1991) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01975823 · Cited by 102
Self-citationLeenders, A. C. A. P., de Marie, S., ten Kate, M. T., Bakker‐Woudenberg, I. A. J. M., & Verbrugh, H. A. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.2.215 · Cited by 86
Adler‐Moore, J., Chiang, S.-M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J., & Proffitt, R. T. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.63 · Cited by 81
Self-citationBoswell, G. W., Bekersky, I., Buell, D. N., Hiles, R., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.263 · Cited by 72
van Etten, E. W. M., Groot, C. V. D. H.-D., & Bakker‐Woudenberg, I. A. J. M. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.5.723 · Cited by 71
Safety and Toxicokinetics of Intravenous Liposomal Amphotericin B (AmBisome ®) in Beagle Dogs
Bekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. N., & Walsh, T. J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018997730462 · Cited by 63
García, A. C., Adler‐Moore, J., & Proffitt, R. T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2327-2332.2000 · Cited by 55
Self-citationGangneux, J., Sulahian, A., GARIN, Y. J. F., Farinotti, R., & Derouin, F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1214 · Cited by 52
Clancy, C. J., & Nguyen, M. H. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.1.127 · Cited by 37
Cited by
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 886
Cornely, O. A., Maertens, J., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heussel, C. P., Lortholary, O., Rieger, C., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 751
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
“Under the slightly acidic conditions used to prepare liposomes, the amino group of amphotericin B, with its net positive charge, forms an ionic complex with the disteareoyl phosphatidylglycerol thus promoting the retention of amphotericin B within the liposomal bilayer [5, 6].”
Metadata
- Authors
- Adler-Moore, J., & Proffitt, R. T.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 49
- Issue
- suppl_1
- Pages
- 21-30
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2146431258
- Cited by
- 339
- References
- 18
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.